Compare · NTRA vs TLSI
NTRA vs TLSI
Side-by-side comparison of Natera Inc. (NTRA) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $39.72B, about 157.8x TLSI ($251.8M).
- Over the past year, NTRA is up 87.1% and TLSI is down 12.7% - NTRA leads by 99.8 points.
- NTRA has been more active in the news (24 items in the past 4 weeks vs 8 for TLSI).
- NTRA has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- Natera Inc.
- TriSalus Life Sciences Inc.
- Price
- $277.42+1.60%
- $4.10+2.24%
- Market cap
- $39.72B
- $251.8M
- 1M return
- +30.75%
- +7.89%
- 1Y return
- +87.13%
- -12.67%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 24
- 8
- Recent ratings
- 25
- 6
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest NTRA
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
- Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
- Director Lynch Thomas J. Jr. was granted 1,905 shares (SEC Form 4)
- Director Marcus Gail Boxer was granted 1,669 shares, increasing direct ownership by 27% to 7,852 units (SEC Form 4)
- Director Botha Roelof was granted 1,691 shares, increasing direct ownership by 58% to 4,585 units (SEC Form 4)
Latest TLSI
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)
- CEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)
- Szela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)
- Chief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)
- Marshak Richard increased direct ownership by 383% to 131,758 units (SEC Form 5)
- Chief Medical Officer Marshall Richard Henry was granted 60,000 shares, increasing direct ownership by 200% to 90,000 units (SEC Form 4)
- New insider Marshall Richard Henry claimed ownership of 30,000 shares (SEC Form 3)
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.